Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Octreotide Market Forecast: What Value Will The Market Reach By 2030?
The octreotide market size has demonstrated consistent expansion over recent years. Looking ahead, its valuation is projected to increase from $2.56 billion in 2025 to $2.69 billion in 2026, registering a compound annual growth rate (CAGR) of 5.0%. Historically, this growth has been driven by factors such as successful clinical outcomes in treating acromegaly, an increase in the diagnosis of neuroendocrine tumors, the introduction of depot formulations, the expansion of specialized endocrine care, and the widespread adoption of hospital-based hormone therapies.
The octreotide market is projected to experience consistent expansion over the coming years. Its valuation is set to reach $3.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.9%. This anticipated increase during the forecast period is driven by factors such as a rise in the demand for long-acting injectables, a growing incidence of endocrine disorders, broadening oncology applications, enhanced hospital infusion capabilities, and advancements in sustained-release formulations. Key developments expected in this period encompass the expanded application in managing hormonal disorders, greater acceptance of long-acting injectable formulations, progress in treating neuroendocrine tumors, an escalating need for hospital-administered treatments, and a heightened emphasis on symptom alleviation in chronic conditions.
Get A Free Sample Report With In-Depth Market Insights:
Octreotide Market Growth Drivers: What’s Behind The Acceleration?
Future expansion of the octreotide market is anticipated to be driven by the rising incidence of cancer. Cancer refers to a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the organism. The surge in cancer cases can largely be attributed to demographic shifts like aging populations, various environmental influences, individual lifestyle decisions, and advancements in diagnostic techniques. Octreotide assists in combating the growing cancer rates by impeding tumor development, managing cancers linked to hormones, and relieving accompanying symptoms. For example, data released in May 2024 by the National Cancer Institute (NCI), a US government entity, indicated approximately 20 million new cancer diagnoses and 9.7 million fatalities globally, with forecasts for 2040 projecting an increase to 29.9 million cases and 15.3 million deaths. Consequently, the expanding prevalence of cancer is a key factor propelling the octreotide market’s advancement.
Octreotide Market Segment Breakdown: Which Categories Lead On Revenue?
The octreotide market covered in this report is segmented –
1) By Type: Octreotide Acetate, Octreotide, Octreotide Chloride, Octreotide Hydrochloride, Indium In-111 Octreotide
2) By Form: Injection, Powder, Microspheres
3) By Indications: Diarrhea, Acromegaly, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-user: Pharmaceutical, Clinical Research
Subsegments:
1) By Octreotide Acetate: Injectable Formulation, Depot Injectable Formulation
2) By Octreotide: Injectable Formulation, Oral Formulation
3) By Octreotide Chloride: Injectable Formulation, Lyophilized Powder
4) By Octreotide Hydrochloride: Injectable Formulation, Lyophilized Powder
5) By Indium In-111 Octreotide: Diagnostic Radiopharmaceutical Formulation, Therapeutic Radiopharmaceutical Formulation
Octreotide Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the octreotide market are concentrating on developing innovative offerings, such as injectable suspensions, to enhance patient adherence and convenience. Injectable suspensions are rapid-acting medications administered via injection, enabling quicker absorption into the bloodstream and bypassing the digestive system for a faster onset of action. For instance, in October 2024, Teva Pharmaceuticals, an Israel-based pharmaceutical company, introduced the generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension), specifically engineered for injection to achieve swift bloodstream absorption. Octreotide is a synthetic analog of the natural hormone somatostatin and is primarily utilized for treating conditions like acromegaly, carcinoid syndrome, and VIP-secreting tumors. This injectable delivery method offers a quicker onset of action compared to traditional oral tablets, simplifying adherence to treatment plans for patients.
Octreotide Market Leading Players And Competitive Positioning
Major companies operating in the octreotide market are Novartis International AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Bachem Holding AG, Chemi S.p.A., LGM Pharma LLC, Hainan Shuangcheng Pharmaceuticals Co. Ltd., USV Private Limited, ChemWerth Inc., Shanghai Soho-Yiming Pharmaceuticals Co. Ltd., Neiss Labs Private Limited, Samarth Life Sciences Private Limited, TAPI Technology & API Services, BCN Peptides S.A.
View The Full Octreotide Market Report:
Octreotide Market Regional Analysis And Leading Geography
North America was the largest region in the octreotide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the octreotide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model